标题:Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
作者:Zhang, Zhen; Zhang, Daoguang; Liu, Yang; Yang, Dezhi; Ran, Fansheng; Wang, Michael L.; Zhao, Guisen
作者机构:[Zhang, Zhen; Zhang, Daoguang; Yang, Dezhi; Ran, Fansheng; Zhao, Guisen] Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Key Lab Chem Biol,Dept Med Ch 更多
通讯作者:Zhao, GS
通讯作者地址:[Zhao, GS]Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Key Lab Chem Biol,Dept Med Chem, Jinan 250012, Shandong, Peoples R China.
来源:ARCHIV DER PHARMAZIE
出版年:2018
卷:351
期:7
DOI:10.1002/ardp.201700369
关键词:arthritis; Bruton's tyrosine kinase; BTK inhibitor; leukemia; lymphoma
摘要:B cell receptor (BCR) signaling plays a key role in B cell development and function. Aberrant BCR signaling has been confirmed as a central driver for the pathogenesis of various B cell malignancies. Bruton's tyrosine kinase (BTK) is a vital component of BCR signaling and exhibits overexpression in various B cell leukemias and lymphomas. Inhibiting BTK has been proved as an efficient way for B cell malignancy intervention. Remarkable achievements have been made in the pursuit of selective BTK inhibitors, represented by the success of the irreversible BTK inhibitors, ibrutinib and acalabrutinib. Constantly emerging agents exhibiting superior efficacy and safety in preclinical and clinical studies provide promising therapeutics for the treatment of B cell malignancies.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046630984&doi=10.1002%2fardp.201700369&partnerID=40&md5=924e766037b00ca21dddde9e9693146b
TOP